or Try an Advanced Search...

    Technical Analysis for THAR - Tharimmune, Inc.

    Grade Last Price % Change Price Change
    F 2.17 -2.69% -0.06
    THAR closed down 2.69 percent on Friday, November 15, 2024, on 5 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical THAR trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    1,2,3 Pullback Bullish Bullish Swing Setup -2.69%
    Narrow Range Bar Range Contraction -2.69%
    Inside Day Range Contraction -2.69%
    Wide Bands Range Expansion -2.69%
    Oversold Stochastic Weakness -2.69%
    MACD Bearish Centerline Cross Bearish -0.46%
    Pocket Pivot Bullish Swing Setup -0.46%
    Older End-of-Day Signals for THAR ...

       Recent Intraday Alerts

    Alert Time
    1,2,3, Pullback Entry 1 day ago
    Rose Above Previous Day's High 1 day ago
    Down 3% 1 day ago
    Up 3% 1 day ago
    Down 2 % 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    THAR Chart by TradingView
    Basic chart:

    Profile

    Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis

    Is THAR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 30 Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
    Oct 28 Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
    Sep 30 Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
    Sep 16 Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
    Jul 22 Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
    Jul 17 Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
    Jul 16 Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
    Jun 20 Tharimmune announces $2.08M private placement
    Jun 10 Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
    May 29 Tharimmune to Present at 2024 BIO International Convention
    See more THAR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 76.3875
    52 Week Low 1.835
    Average Volume 1,333,723
    200-Day Moving Average 4.14
    50-Day Moving Average 2.45
    20-Day Moving Average 2.38
    10-Day Moving Average 2.43
    Average True Range 0.40
    RSI (14) 45.05
    ADX 32.79
    +DI 36.20
    -DI 22.04
    Chandelier Exit (Long, 3 ATRs) 5.19
    Chandelier Exit (Short, 3 ATRs) 3.05
    Upper Bollinger Bands 3.17
    Lower Bollinger Band 1.59
    Percent B (%b) 0.37
    BandWidth 66.47
    MACD Line -0.04
    MACD Signal Line 0.00
    MACD Histogram -0.0403
    Fundamentals Value
    Market Cap 5.48 Million
    Num Shares 2.53 Million
    EPS -15.50
    Price-to-Earnings (P/E) Ratio -0.14
    Price-to-Sales 0.00
    Price-to-Book 0.67
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.45
    Resistance 3 (R3) 2.47 2.39 2.41
    Resistance 2 (R2) 2.39 2.32 2.38 2.39
    Resistance 1 (R1) 2.28 2.27 2.33 2.26 2.38
    Pivot Point 2.20 2.20 2.23 2.19 2.20
    Support 1 (S1) 2.09 2.13 2.15 2.08 1.96
    Support 2 (S2) 2.01 2.08 2.00 1.95
    Support 3 (S3) 1.90 2.01 1.93
    Support 4 (S4) 1.89